X
X
Total 393357 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Agranular insular area posterior part layer 5 of ABA 2009 | ILX:0100423 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Agranular insular area posterior part layer 6a of ABA 2009 | ILX:0100424 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Agranular insular area posterior part layer 6b of ABA 2009 | ILX:0100425 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Agranular insular area posterior part of ABA 2009 | ILX:0100426 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Agranular insular area ventral part layer 1 of ABA 2009 | ILX:0100427 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Agranular insular area ventral part layer 5 of ABA 2009 | ILX:0100428 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Agranular insular area ventral part layer 6a of ABA 2009 | ILX:0100429 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Agranular insular area ventral part layer 6b of ABA 2009 | ILX:0100430 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Agranular insular area ventral part of ABA 2009 | ILX:0100431 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| AHP amplitude | Amplitude from first AP onset to minimum voltage, not explicitly fast or slow | ILX:0100432 | 5 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| AHP duration | Time to the maximal afterhyperpolarization following an AP | ILX:0100433 | 5 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| AIDS | Disease of the human immune system caused by the human immunodeficiency virus (HIV). | ILX:0100434 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Air Kerma Rate Reference Date | Reference date of Reference Air Kerma Rate (300A,022A) of Isotope. | ILX:0100435 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Air Kerma Rate Reference Time | Reference time of Air Kerma Rate (300A,022A) of Isotope. | ILX:0100436 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Akinetic-Rigid Variant of Huntington Disease | ILX:0100437 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Alar central lobule | The lobulus centralis is a small square lobule, situated in the anterior cerebellar notch. It overlaps the lingula, from which it is separated by the precentral fissure; laterally, it extends along the upper and anterior part of each hemisphere, where it forms a wing-like prolongation, the alar central lobule. [WP,unvetted]. | ILX:0100438 | 14 | scicrunch | 06/23/2020 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Albedo | A reflective quality restricted to a particular wavelength. | ILX:0100439 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Albendazole | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) Pharmacology: Albendazole is a broad-spectrum anthelmintic. The principal mode of action for albendazole is by its inhibitory effect on tubulin polymerization which results in the loss of cytoplasmic microtubules. Mechanism of action: Albendazole causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules. The loss of the cytoplasmic microtubules leads to impaired uptake of glucose by the larval and adult stages of the susceptible parasites, and depletes their glycogen stores. Degenerative changes in the endoplasmic reticulum, the mitochondria of the germinal layer, and the subsequent release of lysosomes result in decreased production of adenosine triphosphate (ATP), which is the energy required for the survival of the helminth. Due to diminished energy production, the parasite is immobilized and eventually dies. Drug type: Approved. Small Molecule. Drug category: Anthelmintics. Anticestodal Agents. Antiprotozoal Agents. Tubulin Modulators | ILX:0100440 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Alclometasone | Alclometasone is synthetic glucocorticoid steroid for topical use in dermatology as anti-inflammatory, antipruritic, antiallergic, antiproliferative and vasoconstrictive agent. (Wikipedia) Pharmacology: Alclometasone is a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Alclometasone is a selective glucocorticoid receptor agonist. Mechanism of action: The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Alclometasone also binds the corticosteroid receptor. Drug type: Approved. Small Molecule. Drug category: Anti-inflammatory Agents. Antipruritic Agents. Corticosteroids. Glucocorticoids | ILX:0100441 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Alcohol Amnestic Disorder | A mental disorder associated with chronic ethanol abuse ( ALCOHOLISM) and nutritional deficiencies characterized by short term memory loss, confabulations, and disturbances of attention (MeSH). | ILX:0100442 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
About
Base community for the SciCrunch.org infrastructure
Contact Us
X